Genix Pharmaceuticals Corporation
GENPF
Other OTC0.01
USD
- -
- -
Genix Pharmaceuticals Corporation
GENPF
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genix Pharmaceuticals Corporation formulates, manufactures, licenses, markets and distributes nutraceutical and pharmaceutical products with a primary focus on novel over-the-counter nutraceuticals, generic pharmaceuticals and innovative ophthalmic solutions; core offerings include bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels and spirulina powder alongside proprietary nutraceuticals such as Sucanon for blood sugar management, Rechlor for kidney function support, Flu-X for anti-viral and anti-flu applications, and an exclusive Canadian license for levothyroxine sodium (generic Synthroid in eleven dosages); the company also holds global sales and marketing rights (excluding India) to 30 World Health Organization-approved generic prescription ophthalmic drugs, targeting retail outlets, direct-to-consumer channels and e-commerce platforms. Founded in 1993 and headquartered at 300-1055 West Hastings Street in Vancouver, British Columbia, Canada, with a registered office in Grand Prairie, Alberta, Genix operates principally in the pharmaceuticals and nutraceuticals sectors, serving patients, naturopathic doctors, pharmacies and consumers in Canada, the United States, China, Southeast Asia, the United Kingdom and select other countries through channels aligned with integrative medicine, health and complementary alternative medicine trends. In recent developments, Genix closed a non-brokered private placement in September 2025 issuing 2 million units at CAD 0.05 each to raise CAD 100,000 primarily from insiders including the president and CEO for general working capital and new product funding, subject to TSX Venture Exchange approval; earlier in August 2025, the company announced another non-brokered private placement of 2 million units at CAD 0.05 targeting CAD 100,000 in proceeds; Canagen Pharmaceuticals forgave remaining payments totaling CAD 262,500 for Sucanon and Rechlor plus USD 75,000 for Flu-X as of October 31, 2024; the company awaits Health Canada approvals for its 30 generic ophthalmic drugs and levothyroxine sodium, with the latter's final USD 175,000 payment due upon notice of compliance and drug identification numbers issuance, originally anticipated by late 2024 but delayed; fiscal 2024 sales fell 67% to CAD 4,051 amid reduced online nutraceutical sales, with a net loss of CAD 246,855 and working capital deficiency of CAD 1.19 million, underscoring ongoing reliance on equity financings.
Genix Pharmaceuticals Announces Change To CFO
Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Genix Pharmaceuticals Closes Private Placement
Genix Announces TSX-V Approval of Warrant Amendments
Genix Announces Warrant Repricing and Seeks Extension